Log In
BCIQ
Print this Print this
 

Giazo, balsalazide tablet

Also known as: balsalazide disodium

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionBalsalazide disodium prodrug of 5-aminosalicylic acid (5-ASA)
Molecular Target Unknown
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat mildly to moderately active ulcerative colitis (UC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$12,524.0M

$11,689.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/01/2015

$11,400.0M

$11,400.0M

0

03/11/2015

$1,124.0M

$289.0M

0

Get a free BioCentury trial today